Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
The mucopolysaccharidoses (MPS) are a group of multiple pathology disorders which are part of a larger group of genetic diseases known as lysosomal storage disorders. Enzyme replacement therapy (ERT) has been developed as a therapy for MPS patients. However, immune responses to ERT have been reported in MPS animal models and in human Gaucher patients. Antibodies can have adverse effects during ERT, which include hypersensitivity/anaphylactic reactions, enzyme inactivation, and enzyme degradation. This study aimed to characterize the immune response to ERT in a feline model of MPS VI, by defining the epitope reactivity of cat plasma antibody against human recombinant N-acetylgalactosamine 4-sulfatase (4-sulfatase) replacement protein. For MPS VI cat plasma, antibody reactivity was observed prior to ERT, with distinct regions of 4-sulfatase linear sequence displaying low affinity antibody reactivity. There was an increase in antibody titer to 4-sulfatase for MPS VI cats post-ERT, with the majority of the immune response detected to linear sequence epitopes. One cat displayed a high titer and high affinity epitope reactivity following prolonged exposure (>/=9 months) to the replacement protein. MPS VI cats on shorter term ERT (3 months) showed high titers to 4-sulfatase and similar patterns of epitope reactivity, but lower affinity antibody reactivity, when compared to the latter cat. This study reports the linear amino acid sequence reactivity and nature of the immune response produced to 4-sulfatase before and after ERT. The monitoring of antibody production during replacement therapy is an important consideration for patient management, as high titer antibodies can affect the efficacy of therapy.
Turner
C T
CT
Department of Chemical Pathology, Women's and Children's Hospital, North Adelaide, South Australia, 5006, Australia.
Hopwood
J J
JJ
Bond
C S
CS
Brooks
D A
DA
D000818:Animals; D000906:Antibodies / Q000097:blood*; D002415:Cats; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D008958:Models, Molecular; D009087:Mucopolysaccharidosis VI / Q000188:drug therapy* / Q000276:immunology*; D020051:N-Acetylgalactosamine-4-Sulfatase / Q000276:immunology* / Q000627:therapeutic use*; D011489:Protein Denaturation; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome
D000906:Antibodies; D000939:Epitopes; D011994:Recombinant Proteins; D020051:N-Acetylgalactosamine-4-Sulfatase